** Shares of Akero Therapeutics AKRO.O up 1.8% premarket to $52.39 after co raises more equity than targeted
** Co late Tues said sold ~7.3 mln shares, including ~2 mln pre-funded warrants, at $48 for approx $350 mln gross proceeds
** On Mon, AKRO shares surged 97.5% to $51.71 after co said its lead drug, efruxifermin, showed it can help reverse scarring in patients with type of fatty liver disease known as metabolic dysfunction-associated steatohepatitis (MASH)
** Shares on Tues edged down 0.5% and closed at $51.47 as co marketed $300 mln offering
** Co has ~69.8 mln shares outstanding for $3.6 bln market cap, per LSEG
** JP Morgan, Morgan Stanley and Jefferies are jt bookrunners for the offering
** Separately, 89Bio ETNB.O raised $250 mln of equity to fund its MASH drug candidate
(Lance Tupper is a Reuters market analyst. The views expressed are his own)
((lance.tupper@tr.com 1-646-279-6380))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。